JP2020529988A5 - - Google Patents

Download PDF

Info

Publication number
JP2020529988A5
JP2020529988A5 JP2020505233A JP2020505233A JP2020529988A5 JP 2020529988 A5 JP2020529988 A5 JP 2020529988A5 JP 2020505233 A JP2020505233 A JP 2020505233A JP 2020505233 A JP2020505233 A JP 2020505233A JP 2020529988 A5 JP2020529988 A5 JP 2020529988A5
Authority
JP
Japan
Prior art keywords
group
substituted
compound according
group substituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020505233A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020529988A (ja
JP7498108B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/045175 external-priority patent/WO2019028357A1/en
Publication of JP2020529988A publication Critical patent/JP2020529988A/ja
Publication of JP2020529988A5 publication Critical patent/JP2020529988A5/ja
Application granted granted Critical
Publication of JP7498108B2 publication Critical patent/JP7498108B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020505233A 2017-08-03 2018-08-03 医学的障害の予防および治療のための化合物およびその使用 Active JP7498108B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762540860P 2017-08-03 2017-08-03
US62/540,860 2017-08-03
PCT/US2018/045175 WO2019028357A1 (en) 2017-08-03 2018-08-03 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF MEDICAL DISORDERS AND USES THEREOF

Publications (3)

Publication Number Publication Date
JP2020529988A JP2020529988A (ja) 2020-10-15
JP2020529988A5 true JP2020529988A5 (enExample) 2021-09-09
JP7498108B2 JP7498108B2 (ja) 2024-06-11

Family

ID=65233534

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020505233A Active JP7498108B2 (ja) 2017-08-03 2018-08-03 医学的障害の予防および治療のための化合物およびその使用

Country Status (12)

Country Link
US (3) US11583530B2 (enExample)
EP (1) EP3661502A4 (enExample)
JP (1) JP7498108B2 (enExample)
KR (1) KR102692840B1 (enExample)
CN (1) CN111032039B (enExample)
AU (1) AU2018309085B2 (enExample)
BR (1) BR112020001698A2 (enExample)
CA (1) CA3069745A1 (enExample)
IL (1) IL272097B2 (enExample)
MX (1) MX2020001256A (enExample)
WO (1) WO2019028357A1 (enExample)
ZA (1) ZA202000375B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI744300B (zh) * 2016-03-23 2021-11-01 里爾中央醫學中心 改良性熱處理的血小板顆粒裂解液在製備用於治療神經系統疾病的組合物的用途
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
CN111032039B (zh) 2017-08-03 2024-03-26 卡莱克汀科学有限责任公司 用于预防和治疗医学障碍的化合物及其用途
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
CN117897406A (zh) * 2021-06-08 2024-04-16 真和制药有限公司 抗gal3抗体及其用于胰岛素抵抗的方法
CN113476442A (zh) * 2021-07-28 2021-10-08 上海交通大学医学院附属第九人民医院 化合物gb-0139在治疗心肌梗死后心肌过度纤维化的药物中的应用
GB2631509A (en) * 2023-07-04 2025-01-08 Univ Liverpool Compositions
GB2631507A (en) * 2023-07-04 2025-01-08 Univ Liverpool Compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT377586B (de) * 1981-06-30 1985-04-10 Erba Farmitalia Verfahren zur herstellung von substituierten pyrrolo-(2,1-b)-chinazolinen und pyrido(2,1-b)chinazolinen
IL69274A (en) * 1982-08-05 1986-08-31 Erba Farmitalia (substituted amino)derivatives of 3-benzylidene-pyrrolo(2,1-b)quinazolin-9-ones and 6-benzylidene-pyrido(2,1-b)quinazolin-11-ones,their preparation and pharmaceutical compositions containing them
SE0100172D0 (sv) * 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
EP1363638A4 (en) 2001-01-31 2010-01-06 Lundbeck & Co As H USE OF GAL3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND / OR ANXIETIES AND USEFUL CONNECTIONS FOR SUCH PROCEDURES
US20030078271A1 (en) 2001-01-31 2003-04-24 Blackburn Thomas P. Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
JP4498922B2 (ja) * 2002-07-09 2010-07-07 アクテリオン ファーマシューティカルズ リミテッド 7,8,9,10−テトラヒドロ−6H−アゼピノ、6,7,8,9−テトラヒドロ−ピリドおよび2,3−ジヒドロ−2H−ピロロ[2,1−b]−キナゾリノン誘導体
US7220775B2 (en) 2002-08-07 2007-05-22 H. Lundbeck A/S Compound useful for the treatment of neuropathic pain
DE10304141B4 (de) * 2003-02-03 2006-03-09 Hf Arzneimittelforschung Gmbh Verfahren zur Herstellung von Chinazolin-Alkaloiden
WO2012158913A2 (en) * 2011-05-17 2012-11-22 Discoverybiomed Inc. Treating protein folding disorders with small molecule cftr correctors
ES2562903T3 (es) * 2011-07-13 2016-03-09 Santen Pharmaceutical Co., Ltd Nuevo compuesto que tiene actividad inhibidora de PARP
WO2016004093A2 (en) * 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof
CA2970062C (en) 2015-01-30 2023-02-28 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
CN105272986A (zh) * 2015-06-15 2016-01-27 厦门医学高等专科学校 一种可抑制乙酰胆碱酯酶活性的化合物或其制备方法和应用
CN106220631B (zh) * 2016-07-26 2019-02-05 中山大学 一种7位氟取代Isaindigotone衍生物及其制备方法和在制备抗癌药物中的应用
CN111032039B (zh) 2017-08-03 2024-03-26 卡莱克汀科学有限责任公司 用于预防和治疗医学障碍的化合物及其用途

Similar Documents

Publication Publication Date Title
JP2020519625A5 (enExample)
JP2004529874A5 (enExample)
JP2020531418A5 (enExample)
JP2009530398A5 (enExample)
CN113453721B (zh) Metap2抑制剂的生物标志物及其应用
EP2723340B1 (en) Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
EP2343292A1 (en) Novel prostaglandin i<sb>2</sb>derivative
JP2007508238A5 (enExample)
RU2013122898A (ru) Похоксимовые конъюгаты, применимые для лечения связанных с hsp90 патологий, композиция и способ лечения с их помощью
BRPI0612266A2 (pt) composição fermacêutica, e, uso da mesma
JP2009508902A5 (enExample)
CN101822841A (zh) 有机胺衍生物作为小分子药物脑靶向修饰基团的用途
WO2024230728A1 (zh) 靶向成纤维细胞活化蛋白的配体
WO2025051266A1 (zh) 杂芳环衍生物的lpar1拮抗剂及其用途
JP2008506723A (ja) 医薬用運搬体及び作用体並びに化学用相間移動剤としてのアンモニウム塩及びアンモニウム塩−鉱酸塩クラスレート化合物
CN104557870B (zh) 一种吡啶胺化合物的富马酸盐
CA2658950A1 (en) New macrolides useful against inflammatory and allergic diseases
WO2025162280A1 (zh) 吡唑羧酸衍生物及其在医药上的应用
EP1005347A1 (en) Macrophage scavenger receptor antagonists for use in the treatment of cardiovascular diseases
US9376432B2 (en) Use of VEGFR-3 inhibitors for treating hepatocellular carcinoma
CN103373986A (zh) 克里唑替尼前药及其制备方法与用途
JP2011500841A5 (enExample)
RU2010120810A (ru) Гидратированные кристаллические сложные эфиры камптотецина для лечения рака
JP7819298B2 (ja) Ep4拮抗剤化合物及びその塩、結晶多形並びに使用
CN115279761A (zh) 咪唑并吡啶酮化合物或其盐的晶体